Q32 Bio Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Q32 Bio Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $53.74M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($6.65M) | Mar 11, 2025 |
| FY2018 | Dec 31, 2018 | $3.68M | Mar 12, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $1.16M | Mar 13, 2024 |
| FY2023 | Dec 31, 2022 | $3.21M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $33.97M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $2.70M | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | $1.67M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $5.32M | Mar 12, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $29.82M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($47.73M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($53.74M) | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | ($5.01M) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | ($95.76M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($128.69M) | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | ($103.92M) | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | ($55.58M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | ($29.99M) | Mar 12, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.90M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($66.10M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($48.26M) | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | ($133.28M) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | ($95.95M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($130.26M) | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | ($109.94M) | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | ($59.93M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | ($29.66M) | Mar 12, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $61.78M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $92.33M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $47.06M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $228.47M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $211.72M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $263.74M | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | $310.57M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $259.09M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $137.53M | Mar 12, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.76M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $86.66M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $118.53M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $50.49M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $42.07M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $67.74M | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | $52.06M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $62.74M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $39.22M | Mar 12, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.01M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $5.68M | Mar 10, 2026 |
| FY2025 | Dec 31, 2023 | ($182.92M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2022 | ($130.71M) | Mar 11, 2025 |
| FY2023 | Dec 31, 2021 | $169.65M | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | $196.00M | Mar 9, 2023 |
| FY2021 | Dec 31, 2019 | $258.51M | Mar 23, 2022 |
| FY2020 | Dec 31, 2018 | $196.36M | Mar 11, 2021 |
| FY2019 | Dec 31, 2017 | ($39.45M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2016 | ($9.89M) | Mar 12, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | (5) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | (153) | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 9, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | (6) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | (153) | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 9, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $48.30M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $77.97M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $25.62M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $33.99M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $108.38M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $217.43M | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | $53.77M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $38.22M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $51.58M | Mar 12, 2019 |
| FY2018 | Dec 31, 2016 | $11.39M | Mar 12, 2019 |